<prompt> Answer this question truthfullyWhat is the definition of intraprocedural stent thrombosis?  <response>: <reason> IPST significantly reduces the overall success rate of PCI, as measured by frequency of achieving TIMI flow grade 3 at the end of index PCI. TIMI flow grade 3 is achieved in 90.9 of patients without IPST vs. 44.7 in patients with IPST. Given its significant and unique role in outcome, there is currently increasing advocacy to routinely report IPST in PCI and to add it as a distinctive entity in the Academic Research Consortium ARC definition of stent thrombosis. Intraprocedural and follow-up data on patients who experience IPST reveal the most common significant complications. The occurrence of IPST remarkably increases the risk of occurrence of IPTE-related complications. The following table summarizes intra-procedural complications of IPST. Similar to IPTE in general, IPST is an important independent predictor of mortality and morbidity one year post-PCI. One year follow-up data shows a 41.1 rate of death, MI, or TVR in patients who had experienced IPST vs. only 14.5 in patients with no IPST. Other adverse events were also increased in patients with IPST after one year post-PCI, such as postprocedural stent thrombosis, TVR, and non-CABG major bleeding. The reduction in IPST with cangrelor in CHAMPION PHOENIX contributed to this agents effectiveness in reducing the rates of ARC-defined stent thrombosis and MI. These data provide strong evidence for a significant association between IPST and adverse short-term clinical outcomes after PCI and support the inclusion of IPST as an important endpoint in future pharmacological and device trials . 